TEL AVIV, ISRAEL / VANCOUVER, CANADA - Clearmind Medicine Inc. (NASDAQ:CSE: CMND), (FSE: CWY), a biotechnology firm specializing in the development of psychedelic-derived therapeutics, announced today that it has received divisional patent approval from the China National Intellectual Property Administration. This patent further strengthens the company's intellectual property rights surrounding its primary molecule, MEAI, which is being developed as a treatment for Alcohol Use Disorder (AUD) and other binge behaviors.
The company's intellectual property portfolio now includes 15 patent families, with 27 patents granted and 24 pending applications across significant markets like the United States, Europe, China, and India. Dr. Adi Zuloff-Shani, the CEO of Clearmind said, "We are proud to receive once again recognition of our innovative treatment for binge behaviors. This approval is a major milestone and significantly expands our IP protection as a leader in psychedelic-derived therapeutics."
MEAI, a novel psychoactive compound, has shown promise in reducing the desire to consume alcohol while providing a mild euphoric effect. The company's flagship MEAI-based treatment targets AUD, a prevalent condition ranging from mild to severe, characterized by an individual's inability to limit alcohol intake despite adverse consequences.
This news is based on a press release statement from Clearmind Medicine Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.